Ovarian Cancer Diagnostics and Therapeutics Market

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market by Cancer Types (Epithelial Ovarian Tumor, Ovarian Germ Cell Tumor, and Others) and Modality (Diagnosis [Biopsy, Blood Tests, CT Scan, PET, Ultrasound, and Others] and Therapeutics [Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Others]), and Geography (GCC, South Africa, and Rest of Middle-East and Africa) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-3500
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 165
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Middle East & Africa ovarian cancer diagnostics and therapeutics market size is expected to register a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising burden of ovarian cancer and usage of combination therapies for the treatment of ovarian cancer.

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market key takeaways

Ovarian cancer is a rare form of disease that occurs in a variety of cells within the ovary, an almond-shaped female reproductive organ. Ovarian cancer is caused by mutagenic changes in DNA. Inherited mutations can cause ovarian cancer. The risk of developing cervical cancer is higher if a female undergoes genetic mutations in BRCA1 and BRCA2 genes. The most common type of ovarian cancer is epithelial ovarian cancer (EOC), which arises from the epithelium of the ovary. Cervical cancer ranks 5th in overall female mortality due to cancer. This type of cancer is hardly diagnosed in early stages, making treatment of the complex stage difficult. Ovarian cancer is the seventh of most common cancer among women.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising cases of ovarian cancer and necessity for more effective treatment methods is anticipated to drive the market growth.
  • Development of medicine and chemotherapies is estimated to spur the growth of the market.
  • Increasing importance on early diagnosis & treatment is expected to contribute to the growth of the market.
  • The lack of awareness regarding cancer detection can hamper the market growth.
  • Absence of adequate technology for detection of ovarian cancer and lack of development activities can create challenges for the market.
  • Increasing healthcare expenditure and growing technological advancements can create lucrative opportunities during the forecast period.

Scope of the Report

The report on the Middle East & Africa ovarian cancer diagnostics and therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Cancer Types (Epithelial Ovarian Tumor, Ovarian Germ Cell Tumor, and Others) and Modality (Diagnosis [Biopsy, Blood Tests, CT Scan, PET, Ultrasound, and Others] and Therapeutics [Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Others])

Geographical Scope

GCC Countries, South Africa, and Rest of Middle-East and Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; AstraZeneca plc; Johnson and Johnson (Janssen Pharmaceuticals); and Bristol-Myers Squibb Company

 

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market Segment Insights

Epithelial ovarian tumors segment is anticipated to exhibit a high CAGR

Based on cancer types, the market is categorized as epithelial ovarian tumor, ovarian germ cell tumor, and others. The epithelial ovarian tumor segment is expected to constitute a key share of the market during the projected period. Epithelial tumor is more common in ovarian cancer and cause many conditions, therefore the requirement for a diagnosis of epithelial tumors is much higher than the requirement for a tumor germ cell carcinoma.

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market by cancer types

CT scan segment to hold a major market share

In terms of modality, the Middle East & Africa ovarian cancer diagnostics and therapeutics market is bifurcated into diagnosis and therapeutics. The diagnosis segment is further segregated into biopsy, blood tests, CT scan, Pet, ultrasound, and others. The therapeutics segment is divided into chemotherapy, hormonal therapy, immunotherapy, radiation therapy, and others. Computed Tomography (CT) is a digital imaging technique that uses specialized X-ray imaging to capture images of the underlying body. CT scan device does not accurately detect small tumors in the ovaries, but they can detect large tumors and can be able to detect the growth of nearby tumors. It can also find enlarged lymph nodes, symptoms of cancer spread to the liver or other organs, or signs that the ovarian tumor is affecting the kidneys or bladder. Additionally, growing burden of ovarian cancer and technological advancements are expected to further market growth during the forecast period.

GCC Countries projected to expand at a considerable CAGR

On the basis of geography, the market is classified as GCC Countries, South Africa, and Rest of Middle-East and Africa. GCC Countries are expected to constitute a key share of the market during the projected period. Ovarian cancer is the 11th most common type of cancer in the GCC region. Between January 1998 and December 2004, 1,180 cases of ovarian cancer were reported in all GCC region. Bahrain has reported the highest incidence of ovarian cancer. The mean age group for 100,000 women was 7.4 in Bahrain, followed by Qatar with 6.7, Kuwait with 5.9, Oman with 5.5, the UAE with 4.4, and KSA with 2.3.

Segments

Segments Covered in the Report
The Middle East & Africa ovarian cancer diagnostics and therapeutics market is segmented on the basis of:

Cancer Types

  • Epithelial Ovarian Tumors
  • Ovarian Germ Cell Tumors
  • Others
Modality
  • Diagnosis
    • Biopsy
    • Blood Tests
    • CT Scan
    • PET
    • Ultrasound
    • Others
  • Therapeutics
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Radiation Therapy
    • Others
Geography
  • GCC Countries
  • South Africa
  • Rest of Middle-East and Africa
Key Players
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • AstraZeneca plc
  • Johnson and Johnson (Janssen Pharmaceuticals)
  • Bristol-Myers Squibb Company

Competitive Landscape

The key players competing in the Middle East & Africa ovarian cancer diagnostics and therapeutics market are F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; AstraZeneca plc; Johnson and Johnson (Janssen Pharmaceuticals); and Bristol-Myers Squibb Company.

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ovarian Cancer Diagnostics and Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Ovarian Cancer Diagnostics and Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Ovarian Cancer Diagnostics and Therapeutics Market - Supply Chain
  4.5. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast
     4.5.1. Ovarian Cancer Diagnostics and Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Ovarian Cancer Diagnostics and Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Ovarian Cancer Diagnostics and Therapeutics Market Absolute $ Opportunity
5. Global Ovarian Cancer Diagnostics and Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Ovarian Cancer Diagnostics and Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Ovarian Cancer Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
6. North America Ovarian Cancer Diagnostics and Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Ovarian Cancer Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Ovarian Cancer Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Ovarian Cancer Diagnostics and Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Ovarian Cancer Diagnostics and Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Ovarian Cancer Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
8. Europe Ovarian Cancer Diagnostics and Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Ovarian Cancer Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Ovarian Cancer Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Ovarian Cancer Diagnostics and Therapeutics Market: Market Share Analysis
  11.2. Ovarian Cancer Diagnostics and Therapeutics Distributors and Customers
  11.3. Ovarian Cancer Diagnostics and Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. F. Hoffmann-La Roche Ltd.
     11.4.2. Siemens Healthcare GmbH
     11.4.3. AstraZeneca plc
     11.4.4. Johnson and Johnson (Janssen Pharmaceuticals)
     11.4.5. Bristol-Myers Squibb Company

Segments Covered in the Report
The Middle East & Africa ovarian cancer diagnostics and therapeutics market is segmented on the basis of:

Cancer Types

  • Epithelial Ovarian Tumors
  • Ovarian Germ Cell Tumors
  • Others
Modality
  • Diagnosis
    • Biopsy
    • Blood Tests
    • CT Scan
    • PET
    • Ultrasound
    • Others
  • Therapeutics
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Radiation Therapy
    • Others
Geography
  • GCC Countries
  • South Africa
  • Rest of Middle-East and Africa
Key Players
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • AstraZeneca plc
  • Johnson and Johnson (Janssen Pharmaceuticals)
  • Bristol-Myers Squibb Company

The key players competing in the Middle East & Africa ovarian cancer diagnostics and therapeutics market are F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; AstraZeneca plc; Johnson and Johnson (Janssen Pharmaceuticals); and Bristol-Myers Squibb Company.

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market by key players

Buy Report